Remove Events Remove Vaccine Remove Virus
article thumbnail

Update on the safety of COVID-19 Vaccine AstraZeneca

The Pharma Data

Following a recent concern raised around thrombotic events, AstraZeneca would like to offer its reassurance on the safety of its COVID-19 vaccine based on clear scientific evidence. Safety is of paramount importance and the Company is continually monitoring the safety of its vaccine.

Vaccine 52
article thumbnail

UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is safe and effective

The Pharma Data

Today the Medicines Health Regulatory Authority (MHRA) and European Medicines Agency (EMA) reaffirmed the benefits of COVID-19 Vaccine AstraZeneca continue to far outweigh the risks. Furthermore, there was no evidence of a problem related to specific batches of the vaccine or to particular manufacturing sites.

Vaccine 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AstraZeneca and European Commission reach settlement agreement over vaccine supply,

The Pharma Data

AstraZeneca and the European Commission have reached an agreement that ends legal proceedings over the execution of the Advance Purchase Agreement for the delivery of the COVID-19 vaccine Vaxzevria (ChAdOx1-S [Recombinant]). To date, AstraZeneca and its partners have supplied more than 1.1 Vaxzevria (ChAdOx1-S [Recombinant]).

Vaccine 52
article thumbnail

Ad26.COV2-S Vaccine Seems Safe, Immunogenic for SARS-CoV-2

The Pharma Data

COV2-S Vaccine Seems Safe, Immunogenic for SARS-CoV-2. 13, 2021 — A candidate vaccine, Ad26.COV2.S, 13, 2021 — A candidate vaccine, Ad26.COV2.S, Fever was the most frequent systemic adverse event. Systemic adverse events were less common in cohort 3 versus 1 and for those who received a low versus high dose.

Vaccine 52
article thumbnail

Moderna COVID-19 Vaccine Protection May Last Years, Company Claims

The Pharma Data

Moderna COVID-19 Vaccine Protection May Last Years, Company Claims. 8, 2021 — Moderna CEO Stéphane Bancel said the company’s COVID-19 vaccine may prevent infection for years, CBS News reported Thursday. Professional. FRIDAY, Jan. Natural immunity varies from person to person, CBS News reported. CBS News Article.

Vaccine 52
article thumbnail

COVID-19 nasal vaccine candidate effective at preventing disease transmission

The Pharma Data

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens.

Vaccine 52
article thumbnail

AstraZeneca’s COVID-19 Vaccine Boasts Strong Results with Up to 90% Efficacy

The Pharma Data

As the Pfizer and BioNTech COVID-19 vaccine goes to regulators and the Moderna vaccine approaches the end of its Phase III trials, AstraZeneca and the University of Oxford announced high-level results from an interim analysis of their COVID-19 vaccine, AZD1222. There were no serious adverse safety events.

Vaccine 52